SWOG clinical trial number
SWOG-9450

Prostate Cancer Intervention Versus Observation Trial

Closed
Phase
Published
Abbreviated Title
Local Prostate
Activated
05/01/1995
Closed
11/30/2001

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Age < /= 75 yrs; Clinically localized tissue documented adenoca. of the prostate, (T1 a,b,c, - T2 a,b,c, NX, M0); Diagnosis of CAP within previous 6 mo; PSA < 50 ng/ml,(if currently taking finasteride, PSA < 25 ng/ml); no prior pelvic RT, chemo, anti-androgen or androgen deprivation therapy except 5-alpha-reductase inhibitors; no prior surg. other than TURP/TUIP/dilation/simple prostatectomy; no current estrogen or androgen blocking therapy; no evidence of metastatic dz., no significant medical conditions or high surgical risks (MI within last 6 mo, unstable angina, severe CHF pulmonary or hepatic dz, see p. 31 of the Manual of Operations for complete description).

Publication Information Expand/Collapse

2012

Prostate Cancer - uncertainty and a way forward

IM Thompson;C Tangen New England Journal of Medicine 367(3):270-271 (commentary)

PMid: PMID22808963 | PMC number: n/a (commentary)

1997

The prostate cancer intervention versus observation trial (PIVOT).

TJ Wilt;MK Brawer Oncology 11(8):1133-1139

Other Clinical Trials

SWOG Clinical Trial Number
S2312
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200